



## DECLARATION OF COMPETING INTERESTS OF THE TACKSHS PROJECT RESEARCHERS

Name: **Marta Trapero-Bertran**

The current document indicates the interests for the last 5 years. For any collaborations with tobacco and electronic nicotine delivery system industries life-long period applies (not only last 5 years).

This document is valid during one calendar year and will be annually reviewed and updated.

*Please, add to the table as many rows as necessary and do not delete the ones that are left in blank.*

|  | Institution or company  | Date or period                   | Description   |
|--|---|----------------------------------|---|
| <b>Current employment</b>                              | Universitat Internacional de Catalunya (UIC)  | 2014-currently                   | Lecturer and Senior Researcher on Health Economics  |
| <b>Previous employment</b>                             | Centre for Research on Economics and Health (CRES), Universitat Pompeu Fabra (UPF), Spain;  | 2009-2016                        | Lecturer and Research Fellow on Health Economics  |
|  | University Castilla La-Mancha (UCLM), Spain   | 2013-2015                        | Research Fellow on Health Economics   |
|  | Health Economics Research Group (HERG), Brunel University, UK.  | 2010-2012                        | Lecturer and Research Fellow on Health Economics  |
| <b>Other regular honoraria</b>                         | -   | -                                | -   |
| <b>Other occasional honoraria/benefits<sup>1</sup></b> | Universitat Autònoma de Barcelona; Universidad Castilla La-Mancha; Talento Farmacéutico; Fundación Gaspar Casal; Universitat Pompeu Fabra; Universidad Politécnica de Cartagena; Occasional Advisory Committee or teaching courses on economic evaluation for Pfizer, Sanofi, Novartis, Mundipharma, Janssen, and Merck Sharp & Dohme | Sporadically during last 5 years | Fees for teaching (courses on economic evaluation or give advice as a health economist expert on economic evaluation) |
| <b>Personal travel grants or expenses</b>              | Nothing to declare  | -                                | -   |

<sup>1</sup> This section may include fees for lectures or occasional advisory committees from which you benefit personally. Benefits in kind should also be registered.

|  |   |   |  |
|--|---|---|--|
| <b>for conferences, etc.<sup>2</sup></b>   |   |   |  |
| <b>Membership in boards, advisory committees or similar (including journals)</b> | <p>President from the Spanish Health Economics Association (AES). Spain;</p> <p>Member of the Interim Executive Committee of the European Health Economics Association (EUHEA)</p> <p>Member of the "Committee for the Harmonization of Drug Use in the Field of Primary and Community Care" for the Catalan Government</p> <p>Member of the "Committee for the Harmonization of Drug Use for inpatients - in the hospital, and treatments of high complexity or orphan drugs" for the Catalan Government</p> | <p>2013-2014</p> <p>2013-2014</p> <p>2013-currently</p> <p>2014-currently</p> | <p>Management of the association (around 750 affiliates)</p> <p>Initiating and participating in founding of the European Association of Health Economics (vocal)</p> <p>Expert view on economic evaluation (health economics)</p> <p>Expert view on economic evaluation (health economics)</p> |
| <b>Funding for non-competitive research projects</b>                             | <ol style="list-style-type: none"> <li>1. Referencia: PC2002106. Title "Informe técnico sobre el rigor metodológico del informe de evaluación económica proporcionado por Otsuka Pharmaceutica S.A., en relación al tratamiento de la Hiponatremia i SIADH"</li> <li>2. Guía metodológica para la Estimación de Costes del Asma (GECA)</li> <li>3. Home hospitalization: Return on Investment tool for Spain</li> </ol>   | <p>2013</p> <p>2015-2016</p> <p>2016</p>                                      | <p>Funded by OTSUKA PHARMACEUTICAL S.A, (10.171,00 euros)</p> <p>Funded by Mundipharma (15000eur)</p> <p>Funded by Air Liquide (16000eur)</p>  |
| <b>Intellectual property</b>   | -   | -   | -  |
| <b>Financial interests<sup>3</sup></b>   | Nothing to declare  | -   | -  |
| <b>Non-personal Interests<sup>4</sup></b>  | Fronteras Económicas de las Políticas de Salud (FEPS) ( <a href="http://invesfeps.ulpgc.es/">http://invesfeps.ulpgc.es/</a> ) grant from MINECO   | 2013-2016   | Research associate   |
| <b>Other interests<sup>5</sup></b>   |   |   |  |

<sup>2</sup> Directly or indirectly sponsored by the pharmaceutical, medical equipment and electronic nicotine delivery system industries or any other organisations that could potentially conflict with you work for the TackSHS Project.

<sup>3</sup> It includes stocks and shares in private companies. It does not include pension funds and investment funds where the individual has no influence over its financial management.

<sup>4</sup> Fees, grants, etc., paid to the group or department in which you are personally involved and which are used for research, education, equipment, salaries including benefit in kind and fees for your own work if you do not benefit personally.

|  |   |   |   |
|--|---|---|---|
|  | - | - | - |
|--|---|---|---|

*Place and date*      *Barcelona, 30<sup>th</sup> October 2017*

*Signature*

A handwritten signature in blue ink, appearing to read 'Marta', with a large, stylized flourish that loops around the text.

---

<sup>5</sup> For example, commercial interest of spouse or partner; being trustee or member of outside organisations, including pressure groups, influential groups, civic associations, NGOs, etc.